Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Predictor of clinical relapse among patients with ulcerative colitis

This month's issue of the American Journal of Gastroenterology explores histological disease activity as a predictor of clinical relapse among patients with ulcerative colitis.

News image

fiogf49gjkf04
Endoscopic remission in ulcerative colitis (UC) is associated with improved clinical outcomes. 

Dr Loren Laine and colleagues from Connecticut, USA assessed whether histological remission predicts clinical outcomes, estimated the magnitude of effect, and determined whether histological remission provides additional prognostic utility beyond clinical or endoscopic remission.

Bibliographic databases were searched for studies in inflammatory bowel disease providing baseline histological status and relation to an outcome of clinical relapse or exacerbation. 

The research team's primary analysis compared the proportion of patients with study-defined histological remission vs. the proportion with histological activity who developed clinical relapse/exacerbation. 

The team used additional analyses to compare the proportion with relapse/exacerbation for the presence vs. absence of different histological features and for histological remission vs. endoscopic remission and clinical remission. 

The team identified 15 studies that met inclusion criteria. 

The major methodological shortcoming was lack of blinding of the assessor of clinical relapse/exacerbation to baseline histological status in 13 of the 15 studies. 

The researchers found that relapse/exacerbation was less frequent with baseline histological remission vs. histological activity, and vs. baseline clinical and endoscopic remission. 

Relapse/exacerbation was also less common in the absence vs. presence of specific histological features: neutrophils in epithelium, neutrophils in lamina propria, crypt abscesses, eosinophils in the lamina propria, and chronic inflammatory cell infiltrate. 

The research team observed that histological remission was present in 71% of the 1360 patients with combined endoscopic and clinical remission at baseline.

Dr Laine's team comments, "UC patients with histological remission have a significant 52% relative risk reduction in clinical relapse/exacerbation compared with those with histological activity."

"Histological remission is also superior to endoscopic and clinical remission in predicting clinical outcomes."

"As about 30% of patients with endoscopic and clinical remission still have histological activity, addition of histological status as an end point in clinical trials or practice has the potential to improve clinical outcomes."
,
Endoscopic remission in ulcerative colitis (UC) is associated with improved clinical outcomes. 

Dr Loren Laine and colleagues from Connecticut, USA assessed whether histological remission predicts clinical outcomes, estimated the magnitude of effect, and determined whether histological remission provides additional prognostic utility beyond clinical or endoscopic remission.

Bibliographic databases were searched for studies in inflammatory bowel disease providing baseline histological status and relation to an outcome of clinical relapse or exacerbation. 

The research team's primary analysis compared the proportion of patients with study-defined histological remission vs. the proportion with histological activity who developed clinical relapse/exacerbation. 

The team used additional analyses to compare the proportion with relapse/exacerbation for the presence vs. absence of different histological features and for histological remission vs. endoscopic remission and clinical remission. 

The team identified 15 studies that met inclusion criteria. 

The major methodological shortcoming was lack of blinding of the assessor of clinical relapse/exacerbation to baseline histological status in 13 of the 15 studies. 

The researchers found that relapse/exacerbation was less frequent with baseline histological remission vs. histological activity, and vs. baseline clinical and endoscopic remission. 

Relapse/exacerbation was also less common in the absence vs. presence of specific histological features: neutrophils in epithelium, neutrophils in lamina propria, crypt abscesses, eosinophils in the lamina propria, and chronic inflammatory cell infiltrate. 

The research team observed that histological remission was present in 71% of the 1360 patients with combined endoscopic and clinical remission at baseline.

Dr Laine's team comments, "UC patients with histological remission have a significant 52% relative risk reduction in clinical relapse/exacerbation compared with those with histological activity."

"Histological remission is also superior to endoscopic and clinical remission in predicting clinical outcomes."

"As about 30% of patients with endoscopic and clinical remission still have histological activity, addition of histological status as an end point in clinical trials or practice has the potential to improve clinical outcomes."
,
Endoscopic remission in ulcerative colitis (UC) is associated with improved clinical outcomes. 

Dr Loren Laine and colleagues from Connecticut, USA assessed whether histological remission predicts clinical outcomes, estimated the magnitude of effect, and determined whether histological remission provides additional prognostic utility beyond clinical or endoscopic remission.

Bibliographic databases were searched for studies in inflammatory bowel disease providing baseline histological status and relation to an outcome of clinical relapse or exacerbation. 

The research team's primary analysis compared the proportion of patients with study-defined histological remission vs. the proportion with histological activity who developed clinical relapse/exacerbation. 

The team used additional analyses to compare the proportion with relapse/exacerbation for the presence vs. absence of different histological features and for histological remission vs. endoscopic remission and clinical remission. 

The team identified 15 studies that met inclusion criteria. 

The major methodological shortcoming was lack of blinding of the assessor of clinical relapse/exacerbation to baseline histological status in 13 of the 15 studies. 

The researchers found that relapse/exacerbation was less frequent with baseline histological remission vs. histological activity, and vs. baseline clinical and endoscopic remission. 

Relapse/exacerbation was also less common in the absence vs. presence of specific histological features: neutrophils in epithelium, neutrophils in lamina propria, crypt abscesses, eosinophils in the lamina propria, and chronic inflammatory cell infiltrate. 

The research team observed that histological remission was present in 71% of the 1360 patients with combined endoscopic and clinical remission at baseline.

Dr Laine's team comments, "UC patients with histological remission have a significant 52% relative risk reduction in clinical relapse/exacerbation compared with those with histological activity."

"Histological remission is also superior to endoscopic and clinical remission in predicting clinical outcomes."

"As about 30% of patients with endoscopic and clinical remission still have histological activity, addition of histological status as an end point in clinical trials or practice has the potential to improve clinical outcomes."

Am J Gastroenterol 2016; 111:1692–1701
13 December 2016

Go to top of page Email this page Email this page to a colleague

 24 May 2018 
Precision medicine for tumors
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 23 May 2018 
High body mass index is and ulcerative colitis
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
Fecal incontinence and quality of life in IBD
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Post‐operative complications in elderly IBD
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Esophageal dilatation in clinical practice 
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's
 24 April 2018 
Microbiome in athletes vs sedentary subjects
 23 April 2018 
Genome-wide study on HBV-related acute-on-chronic liver failure

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us